Literature DB >> 11424090

Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A.

Y Murase1, N Okahashi, T Koseki, K Itoh, N Udagawa, O Hashimoto, H Sugino, T Noguchi, T Nishihara.   

Abstract

Bone tissues reportedly contain considerable amounts of activin A and follistatin, an activin A-binding protein. In the present study, we found that follistatin strongly inhibited osteoclast formation in cocultures of mouse bone marrow cells and primary osteoblasts induced by 1alpha,25 dihydroxyvitamin D(3), prostaglandin E(2), and interleukin-1alpha. Antibody aganist activin A also inhibited the osteoclast formation. Furthermore, activin A synergistically stimulated osteoclast differentiation mediated by receptor activator NF-kappaB ligand (RANKL). RT-PCR analysis revealed that osteoblasts produced not only activin A but also follistatin. Western blot analysis of a panel of phosphorylated proteins revealed that activin A stimulated the phosphorylation of p44/42 mitogen activated protein (MAP) kinase (ERK1/2) and p38 MAP kinase in macrophage colony-stimulating factor-dependent bone marrow macrophages (M-BMMPhis). In addition, phosphorylation of Smad2 was observed in M-BMMPhis stimulated with activin A. These findings indicate that the phosphorylation of p44/42 MAP kinase, p38 MAP kinase, and Smad2 is involved in activin A-enhanced osteoclast differentiation induced by RANKL. Taken together, these results suggest that both activin A and follistatin produced by osteoblasts may play an important role in osteoclast differentiation through MAP kinases and Smad2 signaling pathways. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11424090     DOI: 10.1002/jcp.1113

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia.

Authors:  Kristian L Jones; Ashley Mansell; Shane Patella; Bernadette J Scott; Mark P Hedger; David M de Kretser; David J Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

2.  Serum follistatin in patients with prostate cancer metastatic to the bone.

Authors:  Francesca Maria Tumminello; Giuseppe Badalamenti; Fabio Fulfaro; Lorena Incorvaia; Marilena Crescimanno; Carla Flandina; Maria Vittoria Sepporta; Gaetano Leto
Journal:  Clin Exp Metastasis       Date:  2010-07-11       Impact factor: 5.150

3.  Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.

Authors:  Youngjae Jeong; Salah A Daghlas; Yixia Xie; Molly A Hulbert; Ferris M Pfeiffer; Mark R Dallas; Catherine L Omosule; R Scott Pearsall; Sarah L Dallas; Charlotte L Phillips
Journal:  J Bone Miner Res       Date:  2018-06-22       Impact factor: 6.741

4.  Activins and follistatins: Emerging roles in liver physiology and cancer.

Authors:  Emanuel Kreidl; Deniz Oztürk; Thomas Metzner; Walter Berger; Michael Grusch
Journal:  World J Hepatol       Date:  2009-10-31

5.  Activin A inhibits RANKL-mediated osteoclast formation, movement and function in murine bone marrow macrophage cultures.

Authors:  Tristan W Fowler; Archana Kamalakar; Nisreen S Akel; Richard C Kurten; Larry J Suva; Dana Gaddy
Journal:  J Cell Sci       Date:  2015-01-20       Impact factor: 5.285

Review 6.  Smad-dependent mechanisms of inflammatory bone destruction.

Authors:  Michelle Fennen; Thomas Pap; Berno Dankbar
Journal:  Arthritis Res Ther       Date:  2016-12-01       Impact factor: 5.156

Review 7.  Influence of the TGF-β Superfamily on Osteoclasts/Osteoblasts Balance in Physiological and Pathological Bone Conditions.

Authors:  Jessica Jann; Suzanne Gascon; Sophie Roux; Nathalie Faucheux
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

8.  Deletion of activin A in mesenchymal but not myeloid cells ameliorates disease severity in experimental arthritis.

Authors:  Vanessa Waltereit-Kracke; Corinna Wehmeyer; Denise Beckmann; Eugenie Werbenko; Julia Reinhardt; Fabienne Geers; Mike Dienstbier; Michelle Fennen; Johanna Intemann; Peter Paruzel; Adelheid Korb-Pap; Thomas Pap; Berno Dankbar
Journal:  Ann Rheum Dis       Date:  2022-04-13       Impact factor: 27.973

Review 9.  Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder.

Authors:  Toshifumi Sugatani
Journal:  Int J Mol Sci       Date:  2018-08-23       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.